30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of lenvatinib mesylate in the NHS in England.

Lenvatinib mesylate, when used in combination with pembrolizumab is recommended as an option for untreated adults with advanced renal cell carcinoma only if:

• Their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria
• Nivolumab with ipilimumab would otherwise be offered
• The companies provide lenvatinib mesylate and pembrolizumab according to the commercial arrangements

Read NICE final appraisal document